ZURICH (Reuters) - Swiss drugmaker Novartis said on Monday a final-stage trial of its Signifor LAR therapy allowed for greater disease control in patients with the endocrine disorder acromegaly than existing therapies.
via Reuters: Health News Read More Here..
No comments:
Post a Comment